An additional Japanese marketing application for ubenimex [Bestatin] has been withdrawn

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1428, 2004-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

European marketing application for semuloparin withdrawn

By  

Reactions Weekly, Vol. 1, Iss. 1414, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Refusal of the marketing authorisation for Sumatriptan Galpharm has been confirmed by the EMA's CHMP.

By  

Reactions Weekly, Vol. 1, Iss. 1380, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Novartis has been granted 5 years of exclusive marketing rights (EMR) for imatinib mesylate [Glivec] in India

By  

Inpharma, Vol. 1, Iss. 1416, 2003-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Participation of Maternal and Fetal CRH in Early Phases of Human Implantation: The Role of Antalarmin

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 4, Iss. 1, 2004-03 ,pp. : 75-78

Bentham Science Publishers

Access to resources Recommend Favorite

The Significance of Neuroglobin in the Brain

By  

Current Medicinal Chemistry, Vol. 17, Iss. 2, 2010-01 ,pp. : 160-172

Bentham Science Publishers

Access to resources Recommend Favorite